Skip to content

CATALYST PHARMACEUTICALS, INC.: 10-Q filed 2020-08-10

What CATALYST PHARMACEUTICALS, INC. reported in its quarterly report filed 2020-08-10 (fiscal Q2 2020): 42 published measures, 117 facts as tagged in accession 0001193125-20-214907.

This filing

Form
10-Q (quarterly report)
Filed
2020-08-10
Fiscal period
fiscal Q2 2020
Accession
0001193125-20-214907 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All CATALYST PHARMACEUTICALS, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2020-06-30131,411,800USD
At 2019-12-31112,376,230USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2020-06-3020,210,375USD
At 2019-12-3124,746,274USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2020-06-30111,201,425USD
At 2020-03-3199,675,717USD
At 2019-12-3187,629,956USD
At 2019-06-3063,281,567USD
At 2019-03-3151,175,627USD
At 2018-12-3150,783,809USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2020-06-30115,052,248USD
At 2019-12-3189,511,710USD
At 2019-06-3023,417,512USD
At 2018-12-3116,559,400USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2020-04-01 to 2020-06-309,779,987USD91
2020-01-01 to 2020-06-3020,206,002USD182
2020-01-01 to 2020-03-3110,426,015USD91
2019-04-01 to 2019-06-3010,959,948USD91
2019-01-01 to 2019-06-3010,315,445USD181
2019-01-01 to 2019-03-31-644,503USD90

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2020-01-01 to 2020-06-3020,478,188USD182
2019-01-01 to 2019-06-306,057,415USD181

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2019-01-01 to 2019-06-3019,370USD181

Contract revenue excluding tax

Revenue from customer contracts excluding assessed taxes under this specific taxonomy concept. It is not automatically comparable to older revenue tags.

PeriodValueUnitDays
2020-04-01 to 2020-06-3029,604,764USD91
2020-01-01 to 2020-06-3058,741,236USD182
2019-04-01 to 2019-06-3028,837,900USD91
2019-01-01 to 2019-06-3041,286,338USD181

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2020-01-01 to 2020-06-3062,350USD182
2019-01-01 to 2019-06-30281,900USD181

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2020-01-01 to 2020-06-305,000,000USD182
2019-01-01 to 2019-06-30518,797USD181

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2020-06-30-108,482,622USD
At 2019-12-31-128,688,624USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2020-04-01 to 2020-06-30103,414,523shares91
2020-01-01 to 2020-06-30103,410,881shares182
2019-04-01 to 2019-06-30102,869,202shares91
2019-01-01 to 2019-06-30102,808,897shares181

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2020-04-01 to 2020-06-30106,730,423shares91
2020-01-01 to 2020-06-30106,433,862shares182
2019-04-01 to 2019-06-30105,928,970shares91
2019-01-01 to 2019-06-30105,098,930shares181

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2020-04-01 to 2020-06-300.09USD/shares91
2020-01-01 to 2020-06-300.2USD/shares182
2019-04-01 to 2019-06-300.11USD/shares91
2019-01-01 to 2019-06-300.1USD/shares181

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2020-04-01 to 2020-06-300.09USD/shares91
2020-01-01 to 2020-06-300.19USD/shares182
2019-04-01 to 2019-06-300.1USD/shares91
2019-01-01 to 2019-06-300.1USD/shares181

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2020-04-01 to 2020-06-30613,172USD91
2020-01-01 to 2020-06-301,223,137USD182
2019-04-01 to 2019-06-30449,651USD91
2019-01-01 to 2019-06-30449,651USD181

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2020-06-30167,514USD
At 2019-12-31210,467USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2020-04-01 to 2020-06-301,794,462USD91
2020-01-01 to 2020-06-303,313,813USD182
2019-04-01 to 2019-06-30924,996USD91
2019-01-01 to 2019-06-301,858,407USD181

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2020-04-01 to 2020-06-3010,281,890USD91
2020-01-01 to 2020-06-3020,981,637USD182
2019-04-01 to 2019-06-3010,959,189USD91
2019-01-01 to 2019-06-309,971,420USD181

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2020-06-30131,163,687USD
At 2019-12-31111,363,623USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2020-06-3020,210,375USD
At 2019-12-3124,098,742USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2020-06-305,804,778USD
At 2019-12-314,117,447USD

Net current accounts receivable

Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.

PeriodValueUnitDays
At 2020-06-306,762,262USD
At 2019-12-3110,536,997USD

Net inventory

Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.

PeriodValueUnitDays
At 2020-06-301,827,924USD
At 2019-12-311,956,792USD

Selling, general and administrative expense

Selling and general administrative costs reported under this concept. It is an expense category, not a substitute for total operating expenses.

PeriodValueUnitDays
2020-04-01 to 2020-06-3010,833,358USD91
2020-01-01 to 2020-06-3020,896,406USD182
2019-04-01 to 2019-06-308,987,722USD91
2019-01-01 to 2019-06-3017,404,182USD181

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2020-04-01 to 2020-06-304,349,643USD91
2020-01-01 to 2020-06-308,572,454USD182
2019-04-01 to 2019-06-304,629,364USD91
2019-01-01 to 2019-06-307,937,323USD181

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2020-06-30103,422,032shares
At 2019-12-31103,397,033shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2020-06-30219,581,816USD
At 2019-12-31216,205,678USD

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

PeriodValueUnitDays
At 2020-06-30-1,191USD
At 2019-12-319,505USD

Operating lease right-of-use asset

Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.

PeriodValueUnitDays
At 2020-06-3071,711USD
At 2019-12-31793,252USD

Operating lease liability

Present value of remaining operating lease payments. Discount-rate choices and lease terms affect the amount; it is not the sum of undiscounted future rent.

PeriodValueUnitDays
At 2020-06-30197,896USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2020-06-3014,405,597USD
At 2019-12-3119,981,295USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2020-06-307,521,253USD
At 2019-12-314,351,074USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

PeriodValueUnitDays
2020-04-01 to 2020-06-3010,393,159USD91
2020-01-01 to 2020-06-3021,429,139USD182
2019-04-01 to 2019-06-3011,409,599USD91
2019-01-01 to 2019-06-3010,765,096USD181

Profit or loss including noncontrolling interests

Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.

PeriodValueUnitDays
2020-01-01 to 2020-06-3020,206,002USD182
2019-01-01 to 2019-06-3010,315,445USD181

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

PeriodValueUnitDays
2020-04-01 to 2020-06-309,695,045USD91
2020-01-01 to 2020-06-3020,195,306USD182
2019-04-01 to 2019-06-3010,988,394USD91
2019-01-01 to 2019-06-3010,357,451USD181

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2020-01-01 to 2020-06-3042,953USD182
2019-01-01 to 2019-06-3020,186USD181

Other nonoperating income or expense

Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.

PeriodValueUnitDays
2020-04-01 to 2020-06-30111,269USD91
2020-01-01 to 2020-06-30447,502USD182
2019-04-01 to 2019-06-30450,410USD91
2019-01-01 to 2019-06-30793,676USD181

Operating lease payments

Cash paid for operating lease liabilities during the period. It differs from lease expense recognized and excludes variable payments in some presentations.

PeriodValueUnitDays
2020-01-01 to 2020-06-30168,122USD182

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

PeriodValueUnitDays
2020-01-01 to 2020-06-30-3,774,735USD182
2019-01-01 to 2019-06-3010,376,427USD181

Change in inventories

The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.

PeriodValueUnitDays
2020-01-01 to 2020-06-30-128,868USD182
2019-01-01 to 2019-06-30213,867USD181

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2020-01-01 to 2020-06-301,687,331USD182
2019-01-01 to 2019-06-30991,359USD181

Inspect the source

Entity
CATALYST PHARMACEUTICALS, INC. / CIK 0001369568
Captured
2026-09-21T17:19:25.463Z
SEC response SHA-256
7cf76a511a9127dd31ed7d53955bbe348f790d8d7fd354d359e6674e7b2af9c9

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001369568.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))